Motif Bio PLC (LON:MTFB) has received a US Department of Defense grant for clinical research into its antibiotic iclaprim, which will be carried out by the research institute that provides biomedical research for the US army.
In a statement, the company said the Walter Reed Army Institute of Research (WRAIR) will conduct pre-clinical testing to evaluate the antibiotic in novel combinations to improve safety and efficacy when administered in a new aerosol form.
The US government grant is part of the Military Infectious Diseases research program to evaluate the potential of using drug-device combinations for wound care and to prevent and treat wound infections on the battlefield.
Dr Daniel Zurawski, of WRAIR’s wound infections department will lead the aerosol research.
Motif Bio chief executive David Huang said: “When a wound becomes infected, it is critical to provide safe and effective treatment as fast as possible. The data generated from Dr Zurawski's research will be important in understanding whether iclaprim delivered locally could play a role in treating battlefield wound infections.”
Motif was told last month by the US Food and Drug Administration that in order to submit a new drug application for iclaprim as a bacterial pneumonia treatment it would need to carry out a Phase III clinical trial demonstrating safety and efficacy of the drug, along with data on potential mechanisms of hepatic injury.
The AIM-listed company said it would take several years to enrol and complete such a trial and cost tens of millions of dollars, meaning it would need to either find a partner to pay for the trial or else dispose of iclaprim to a firm with deeper pockets.